Introduction
Adeno-associated virus (AAV) vectors are widely used in gene therapy development, and accurate measurement of capsid levels is a critical part of this process.
At first glance, AAV quantification may seem straightforward. However, in practice, it presents a number of challenges—ranging from differences in what is being measured to variability introduced by assay design and sample type.
Understanding these factors is important for selecting the right method and interpreting results correctly.
What Does “AAV Quantification” Actually Mean?
One of the main complexities in AAV analysis is that “quantification” can refer to different things:
- Viral genome (vg) titre
→ measured by qPCR or ddPCR - Total capsid titre
→ measures all viral particles (empty + full) - Full capsid titre
→ measures genome-containing particles only
These measurements provide different information and are not directly interchangeable. For example, vg titre reflects the amount of packaged genetic material, while capsid titre reflects the number of physical particles.
Why Total Capsid Measurement Matters
Total capsid quantification is particularly important during:
- Upstream process development
- Downstream purification
- Process optimisation
It provides a direct measure of how many viral particles are present, regardless of genome content, making it useful for:
- Tracking production yield
- Comparing process conditions
- Monitoring losses during purification
This helps teams understand how each process step affects viral particle recovery and supports more consistent AAV process development.
Challenges in Measuring AAV Capsids
Empty vs Full Capsids
AAV preparations typically contain a mixture of:
- Full capsids (containing genetic material)
- Empty capsids
Most total capsid assays measure both populations together. While this is appropriate for many development workflows, it does not directly reflect functional titre.
Serotype Dependence
AAV exists in multiple serotypes (e.g. AAV2, AAV8, AAV9), each with structural differences in the capsid.
Many capsid quantification methods rely on antibodies that recognise specific epitopes. As a result:
- Some assays are serotype-specific
- Others are designed to recognise multiple serotypes
Selecting an appropriate assay therefore depends on:
- The serotype being used
- Whether cross-reactivity is required
- Consistency across experiments
This makes assay selection an important consideration when comparing AAV capsid measurements across different serotypes or studies.
Antibody Coverage and Assay Design
For antibody-based methods such as ELISA, assay performance depends on:
- Antibody specificity and affinity
- Epitope accessibility on the capsid
- Compatibility with the sample matrix
Differences in antibody binding can influence:
- Signal strength
- Sensitivity
- Comparability between serotypes or conditions
Because of this, assays are often developed using well-characterised antibodies targeting commonly used serotypes or conserved epitopes, depending on whether broad coverage or serotype specificity is required.
Complex Sample Matrices
AAV samples are frequently measured in:
- Crude lysates
- Cell culture media
- Process intermediates
These matrices can introduce background signal or interfere with detection, depending on the method used.
Methods for AAV Capsid Quantification
Several approaches are used for measuring AAV capsids:
- ELISA-based assays
→ widely used for total capsid quantification - Analytical ultracentrifugation (AUC)
→ can distinguish empty and full capsids, but lower throughput - Chromatography-based methods
→ used for detailed characterisation
Each method provides different types of information and is suited to different stages of development.
Workflow Considerations
In early-stage workflows, the priority is often:
- Comparing multiple samples
- Monitoring trends
- Generating results quickly
In these cases, consistency and ease of use are often more important than analytical depth. This makes it important to select methods that fit the workflow, not just the analytical requirement.
Approaches that simplify assay setup or support measurement in complex samples are increasingly used alongside established techniques to improve efficiency during development. For example, platforms such as Amperia™ apply antibody-based detection with an electrochemical readout, offering an alternative way to quantify total capsid levels within a streamlined workflow.
References
- Lock, M., Alvira, M.R. & Wilson, J.M. (2012). Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. Human Gene Therapy Methods
- Sommer, J.M. et al. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Molecular Therapy
Frequently asked questions
What is the difference between total capsid and viral genome titre?
Total capsid titre measures all viral particles (empty and full), while viral genome titre measures only genome-containing particles. The two are not directly interchangeable.
Why do total capsid measurements include empty particles?
Most antibody-based assays detect the capsid structure itself, regardless of whether genetic material is present.
How do I choose the right AAV quantification method?
It depends on the question being asked. Total capsid assays are often used for process monitoring, while genome-based methods are used to assess functional content.
Do different AAV serotypes affect measurement?
Yes. Many assays rely on antibodies, so performance can vary depending on serotype and epitope recognition.